Nodule

MEDO receives FDA approval to Revolutionize Thyroid Ultrasound.

Retrieved on: 
Thursday, May 6, 2021
Anatomy, Branches of biology, Thyroid disease, Endocrine system, Glands, Thyroid, Nodule, Medo, Thyroid cancer

This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.

Key Points: 
  • This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.
  • Using artificial intelligence, Medo has revolutionized the process of performing thyroid studies and turned it into a seamless, fast,and objective workflow.\nWith Medo-Thyroid, the user simply obtains quick video \'sweeps\' of each side of the thyroid gland.
  • Jacob Jaremko, a radiologist and co-founder of Medo, explains that "Medo-Thyroid makes thyroid ultrasound a less frustrating test, by presenting thyroid measurements and nodule characteristics in a convenient format.
  • Dornoosh Zonoobi, co-founder and CEO of Medo, notes that: "With this product, Medo provides both clinical and financial value to the stakeholders.

Teleradiology Leader Receives FDA Clearance for Its Lung Nodule Measurement Tool Built with Artificial Intelligence

Retrieved on: 
Tuesday, March 30, 2021
Medicine, Radiology, Medical specialties, Health care, Medical imaging, Image processing, Telemedicine, Teleradiology, Lung nodule, Food and Drug Administration, Nodule

PALO ALTO, Calif., March 30, 2021 /PRNewswire/ -- Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases.

Key Points: 
  • PALO ALTO, Calif., March 30, 2021 /PRNewswire/ -- Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases.
  • The FDA clearance for NinesMeasure is the second FDA clearance in 10 months for the Silicon Valley based teleradiology practice, demonstrating the company's commitment to transforming the use of technology in radiology.
  • Last April, Nines also received FDA clearance for artificial intelligence technology that triages mass effect conditions and intracranial hemorrhages.
  • Lung nodule measurement can be tedious and time consuming as each nodule has to be measured carefully to determine changes in size over time.

Massive Deposit of Battery-Grade Nickel on Deep-Sea Floor Gets Confidence Boost With New Data

Retrieved on: 
Thursday, January 28, 2021
Physical sciences, Chemistry, Natural sciences, Chemical elements, Dietary minerals, Transition metals, Ferromagnetic materials, Reducing agents, Manganese nodule, Polymetal, Nodule, Nickel

According to some academic forecasts, nickel demand for batteries is projected to jump thirty-fold in the coming three decades.

Key Points: 
  • According to some academic forecasts, nickel demand for batteries is projected to jump thirty-fold in the coming three decades.
  • In addition, the company reported a notable uplift in grades of manganese (2.2% higher), cobalt (5.4% higher) and nickel (6.1% higher).
  • "Unlike mineral exploration on land, resource confidence in polymetallic nodules is unusually high due to the two-dimensional nature of the resource.
  • The polymetallic nodule fields in the CCZ of the Pacific represent the largest known, undeveloped nickel resource on the planet.

Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test

Retrieved on: 
Tuesday, December 1, 2020
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Lung nodule, Anatomical pathology, Lung cancer, Nodule, Branches of biology, Thyroid disease, Medical specialties, Nodify XL2® Lung Nodule Test, Biodesix

Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the companys Nodify XL2 lung nodule test.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the companys Nodify XL2 lung nodule test.
  • In previously published findings from the Pulmonary Nodule Plasma Proteomic Classifier (PANOPTIC) Trial, the Nodify XL2 test was shown to accurately identify patients with lung nodules who have a pre-test risk of malignancy less than 50% as likely benign.
  • This data confirms the performance of the Nodify XL2 test over the guideline-recommended two-year surveillance period to radiologically confirm a benign diagnosis.
  • The Nodify XL2 blood-based proteomic test helps identify patients who have a suspicious lung nodule that is likely benign or at a reduced risk of being cancerous.

Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020

Retrieved on: 
Tuesday, October 20, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Lung cancer, Lung nodule, Anatomy, Nodule, Cancer, Branches of biology, Medical specialties, Rheumatoid nodule, Thyroid nodule

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules.

Key Points: 
  • Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules.
  • Data from these studies, which are being presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung testing strategy and confirm previously reported performance of the Nodify XL2 and Nodify CDT tests.
  • Risk reclassification can reduce invasive procedures on benign nodules and ultimately lead to improved nodule management.
  • Data suggest that while standard risk assessment for lung cancer is imprecise, it can be improved with the blood-based Nodify Lung testing strategy.

New Report Highlights Deep Sea Nodule Mining Danger to Pacific Ocean and Island Nations

Retrieved on: 
Thursday, May 21, 2020
Underwater mining, Manganese nodule, Deep sea mining, Natural Resources, Polymetal, Primary sector of the economy, Economic sectors, Sea, Mining, Nodule, International Seabed Authority

The report, Predicting the impacts of mining deep sea polymetallic nodules in the Pacific Ocean , and commissioned by MiningWatch Canada and the Deep Sea Mining Campaign, also notes that there is little to no social licence to mine deep sea nodules and refutes Canadian company DeepGreen Metals claims that there will be economic gains for Pacific island economies.

Key Points: 
  • The report, Predicting the impacts of mining deep sea polymetallic nodules in the Pacific Ocean , and commissioned by MiningWatch Canada and the Deep Sea Mining Campaign, also notes that there is little to no social licence to mine deep sea nodules and refutes Canadian company DeepGreen Metals claims that there will be economic gains for Pacific island economies.
  • In fact, the best available research clearly indicates that the mining of deep sea nodules will place Pacific island states at great risk.
  • The stakes are extremely high with Pacific economies, cultures, livelihoods, fisheries, food security, tourism, and iconic marine species all under threat from deep sea nodule mining.
  • It raises the question of whether deep sea mining has any place in this modern age of a sustainable blue economy, concluded Rogers.

Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

Retrieved on: 
Monday, November 4, 2019
Oncology, Medical Supplies, Health, Genetics, Cardiology, Biotechnology, Lung nodule, Lung cancer, Nodule, XL2

Biodesix, Inc. the leader in lung cancer diagnostics, today announced that Tri-Star Health in Nashville, TN, the region's largest, most comprehensive healthcare provider, is the first hospital system in the U.S. to adopt the recently launched Nodify XL2 proteomic nodule classifier for incidental lung nodule management.

Key Points: 
  • Biodesix, Inc. the leader in lung cancer diagnostics, today announced that Tri-Star Health in Nashville, TN, the region's largest, most comprehensive healthcare provider, is the first hospital system in the U.S. to adopt the recently launched Nodify XL2 proteomic nodule classifier for incidental lung nodule management.
  • In my experience, Nodify XL2 has been simple to integrate into my clinical assessment and our clinics workflow.
  • The Nodify XL2 test is easy to use; blood can be drawn in the doctors office and sent overnight to the Biodesix lab for processing.
  • Biodesix is the first company to offer four best-in-class non-invasive tests for patients with lung cancer or suspicious lung nodules.

Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

Retrieved on: 
Monday, June 10, 2019
Health, Biotechnology, Genetics, Oncology, Thyroid disease, Anatomy, Glands, Human anatomy, Thyroid cancer, Thyroid nodule, Thyroid, Goosecoid protein, Nodule

The benign call rate among Hrthle cells a common but difficult-to-diagnose thyroid nodule subtype was also significantly higher using the Afirma GSC (88.8 percent vs. 25.7 percent).

Key Points: 
  • The benign call rate among Hrthle cells a common but difficult-to-diagnose thyroid nodule subtype was also significantly higher using the Afirma GSC (88.8 percent vs. 25.7 percent).
  • The new study marks the third recent independent publication by a major medical center demonstrating that its use of the Afirma GSC helped to significantly reduce surgeries in thyroid cancer diagnosis.
  • The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis.
  • Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005635/en/

Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype

Retrieved on: 
Monday, April 8, 2019
Surgery, Health, Biotechnology, Genetics, Medical devices, Oncology, Thyroid disease, Glands, Anatomy, Organ systems, Thyroid nodule, Thyroid cancer, Thyroid, Nodule, Thyroid neoplasm

Most Hrthle cell cases yield inconclusive cytopathology results and, prior to Veracytes next-generation genomic test, most of these patients typically required surgery to rule out thyroid cancer.

Key Points: 
  • Most Hrthle cell cases yield inconclusive cytopathology results and, prior to Veracytes next-generation genomic test, most of these patients typically required surgery to rule out thyroid cancer.
  • While most Hrthle cells in patients with indeterminate thyroid nodules are benign, patients with this thyroid nodule subtype have historically been recommended for surgery because of the possibility of cancer, said Richard T. Kloos, M.D., senior medical director endocrinology, at Veracyte.
  • The Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas provide physicians with a comprehensive solution for a complex landscape in thyroid nodule diagnosis.
  • Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190408005149/en/